

## VIDENSKAB OG PRAKSIS | AKADEMISKE AFHANDLINGER

## Litteratur

1. Sundhedsstyrelsen. Type 2-diabetes. Medicinsk Teknologivurdering. København: Sundhedsstyrelsen, 2003:5.
3. Kangas T, Aro S, Koivisto VA et al. Structure and costs of health care of diabetic patients in Finland. *Diabetes Care* 1996;19:494-7.
4. Green A, Rasmussen SR, Emneus M. Sundhedsøkonomiske omkostninger og benefits ved behandling af diabetes mellitus i Danmark. *Behandlerbladet* 2006;23:6-10.
5. Henriksson F, Jonsson B. Diabetes: the cost of illness in Sweden. *J Intern Med* 1998;244:461-8.
7. Clarke P, Gray A, Legood R et al. The impact of diabetes-related complications on healthcare costs: results from the United Kingdom Prospective Diabetes Study (UKPDS Study No. 65). *Diabet Med* 2003;20:442-50.
8. The DCCT Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. *N Engl J Med* 1993;329:977-86.
9. Hermansen K, Fontaine P, Kukolja KK et al. Insulin analogues (insulin detemir and insulin aspart) versus traditional human insulins (NPH insulin and regular human insulin) in basal-bolus therapy for patients with type 1 diabetes. *Diabetologia* 2004;47:622-9.
10. Heller SR, Colagiuri S, Vaaler S et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with type 1 diabetes. *Diabetic Med* 2004;21:769-75.
12. Palmer AJ, Roze S, Valentine WJ et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. *Curr Med Res Opin* 2004;20(suppl 1):5-26.
13. Palmer AJ, Roze S, Valentine W et al. Validation of the CORE diabetes model against epidemiological and clinical studies. *Curr Med Res Opin* 2004;20(suppl 1):27-40.
14. Clarke P, Gray A, Holman R. Estimating utility values for health states of type 2 diabetic patients using the EQ-5D (UKPDS 62). *Med Decis Making* 2002;22:340-9.
16. The CDC diabetes cost-effectiveness group. Cost-effectiveness of intensive glycaemic control, intensified hypertension control, and serum cholesterol level reductin for type 2 diabetes. *JAMA* 2002;287:2542-51.
17. Gyrd-Hansen D. Willingness to pay for a QALY. *Health econ* 2003;12:1049-60.
18. Lundin D. Kostnadseffektivitet som kriterium for subvention av läkemedel – en bra idé? *Ekonomisk Debatt* 2004;6:32-40.
19. Rawlins MD, Culyer AJ. National institute for clinical excellence and its value judgements. *Br Med J* 2004;329:224-7.
20. Ashwell SG, Amiel SA, Biloust RW et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. *Diabetic Med* 2006;23:285-92.
21. Valentine WJ, Palmer AJ, Erny-Albrecht KM et al. Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of detemir, glargine, and NPH. *Adv Ther* 2006;23:191-207.
22. Palmer AJ, Valentine W, Ray JA et al. An economic assessment of analogue basal-bolus insulin versus human basal-bolus insulin in subjects with type 1 diabetes in the UK. *Curr Med Res Opin* 2007;23:895-901.
23. Palmer AJ, Roze S, Valentine WJ et al. Cost-effectiveness of detemir-based basal/bolus therapy versus NPH-based basal/bolus therapy for type 1 diabetes in a UK setting: an economic analysis based on meta-analysis results of four clinical trials. *Curr Med Res Opin* 2004;20:1729-46.
24. National institute for health and clinical excellence. Technology appraisal no. 53. Guidance on the use of long-acting insulin analogues for the treatment of diabetes – insulin Glargine. London: National Institute of Clinical Excellence, 2002.

## &gt; AKADEMISKE AFHANDLINGER

## 1. reservelæge og ph.d. Lars Rejnmark:

## Diuretics and bone

## Disputats

Forf.s adresse: Medicinsk-Endokrinologisk Afdeling C, Århus Universitetshospital, Århus Sygehus, Tage-Hansens Gade 2, DK-8000 Århus C.

E-mail: rejnmark@post6.tele.dk

Forsvaret fandt sted fredag den 28. marts 2008.

Opponent: Peter Schwarz, Jens Bollerslev og Jørn Olsen.

## Cand.pharm. Jónrit Halling:

## Genetiske variationer i lægemiddelmetabolisme blandt færing

## Ph.d.-afhandling

Forf.s adresse: Klinisk Farmakologi, Syddansk Universitet, Winsløwparken 19, 2. sal, DK-5000 Odense C.

E-mail: jhalling@health.sdu.dk

Forsvaret fandt sted den 25. marts 2008.

Bedømmere: Kim Dalhoff, Henrik Enghusen Poulsen og Kirsten Ohm Kyvik.

Vejledere: Kim Brøsen, Pål Weihe og Philippe Grandjean.

## Læge Søren Hagstrøm:

## New treatment aspects of non-neuropathic daytime urinary incontinence in children

## Ph.d.-afhandling

Forf.s adresse: Højvangsvej 25, DK-9400 Nørresundby.

E-mail: hagstroem@ki.au.dk

Forsvaret fandt sted den 28. marts 2008.

Bedømmere: Wendy Bower, Hongkong, Trygve Nevéus, Sverige, og Troels Munch Jørgensen.

Vejledere: Jens Christian Djurhuus og Søren Rittig.

Find referater af denne uges akademiske afhandlinger på [www.ugeskriftet.dk](http://www.ugeskriftet.dk) under

>Seneste nummer >Akademiske afhandlinger

## &gt; RETTELSE

## Rettelse til originalartiklen »Fyrværkeriskader i Danmark i perioden 1995/1996-2006/2007«

Læge Thomas Foged, overlæge Jens M. Lauritsen og overlæge Tine Ipsen, Odense Universitetshospital, Ortopædkirurgisk Afdeling (Ugeskr Læger 2007;169:4271-5).

I ovennævnte artikel var tredjeforfatters navn angivet forkert. Det korrekte er Tine Ipsen.

Redaktionen beklager fejlen.